Literature DB >> 23305170

Diabetes predicts metastasis after radical prostatectomy in obese men: results from the SEARCH database.

Chenwei Wu1, William J Aronson, Martha K Terris, Joseph C Presti, Christopher J Kane, Christopher L Amling, Stephen J Freedland.   

Abstract

OBJECTIVE: To examine the association between diabetes and metastasis risk after radical prostatectomy (RP) and to determine if race or obesity modifies this relationship. PATIENTS AND METHODS: Patients comprised 2058 US veterans with prostate cancer (PCa) enrolled in the Shared Equal-Access Regional Cancer Hospital (SEARCH) database and treated with RP between 1988 and 2010. The association of diabetes with metastasis risk or secondary treatment rates was examined using Cox proportional hazards, adjusting for preoperative and, separately, clinical and postoperative findings. The effect modification by race (black vs white) and obesity (body mass index [BMI] ≥30 vs <30 kg/m(2) ) was tested via interaction terms.
RESULTS: Men with diabetes had higher BMIs and were more likely to be non-white (all P ≤ 0.001). On multivariable analysis, diabetes was not associated with metastasis risk (P ≥ 0.45), but, among men with diabetes, longer diabetes duration was associated with higher metastasis risk (P ≤ 0.035). When stratified by obesity, diabetes was linked with higher metastasis risk in obese but not in non-obese men (P-interaction ≤ 0.037), but there was no significant interaction with race (P-interaction ≥ 0.56). Diabetes also predicted more aggressive secondary treatment among obese men but less aggressive treatment among non-obese men (hazard ratio 1.39 vs 0.63, P-interaction = 0.006). Where applicable, results were similar for both pre- and postoperative models.
CONCLUSIONS: Diabetes was not associated with metastasis risk overall. Stratification by obesity yielded significant differences, with diabetes linked to a fourfold higher metastasis risk in obese men, despite predicting more aggressive secondary treatment. Longer diabetes duration was also associated with increased metastasis risk.
© 2013 BJU International.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23305170     DOI: 10.1111/j.1464-410X.2012.11687.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  6 in total

Review 1.  Obesity and cancer: mechanistic insights from transdisciplinary studies.

Authors:  Emma H Allott; Stephen D Hursting
Journal:  Endocr Relat Cancer       Date:  2015-09-15       Impact factor: 5.678

2.  Preoperative glycemic control status as a significant predictor of biochemical recurrence in prostate cancer patients after radical prostatectomy.

Authors:  Hakmin Lee; Harim Kuk; Seok-Soo Byun; Sang Eun Lee; Sung Kyu Hong
Journal:  PLoS One       Date:  2015-04-21       Impact factor: 3.240

3.  Author'S reply.

Authors:  Simona Di Francesco; Raffaele L Tenaglia
Journal:  Cent European J Urol       Date:  2014

4.  Diabetes and Prostate Cancer Outcomes in Obese and Nonobese Men After Radical Prostatectomy.

Authors:  Sonia Kelkar; Taofik Oyekunle; Adva Eisenberg; Lauren Howard; William J Aronson; Christopher J Kane; Christopher L Amling; Matthew R Cooperberg; Zachary Klaassen; Martha K Terris; Stephen J Freedland; Ilona Csizmadi
Journal:  JNCI Cancer Spectr       Date:  2021-03-09

5.  The effects of nonspecific HIF1α inhibitors on development of castrate resistance and metastases in prostate cancer.

Authors:  Weranja K B Ranasinghe; Shomik Sengupta; Scott Williams; Mike Chang; Arthur Shulkes; Damien M Bolton; Graham Baldwin; Oneel Patel
Journal:  Cancer Med       Date:  2014-01-27       Impact factor: 4.452

6.  Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database.

Authors:  E H Allott; M R Abern; L Gerber; C J Keto; W J Aronson; M K Terris; C J Kane; C L Amling; M R Cooperberg; P G Moorman; S J Freedland
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-10-08       Impact factor: 5.554

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.